|
|
Volumn 34, Issue 12, 2016, Pages 1428-1429
|
|
Multiple dimensions of value: Evaluative frameworks for new cancer therapies
a b b b b a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
REGORAFENIB;
ANTINEOPLASTIC AGENT;
NEW DRUG;
CANCER RISK;
CANCER THERAPY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL DECISION MAKING;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HUMAN;
LETTER;
METASTATIC COLORECTAL CANCER;
NEOPLASM;
PATIENT ADVOCACY;
PATIENT PREFERENCE;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
SPLEEN SIZE;
COST BENEFIT ANALYSIS;
DECISION SUPPORT SYSTEM;
DRUG COST;
ECONOMIC MODEL;
ECONOMICS;
NEOPLASMS;
PATIENT SELECTION;
QUALITY OF LIFE;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
DECISION SUPPORT TECHNIQUES;
DRUG COSTS;
DRUGS, INVESTIGATIONAL;
HUMANS;
MODELS, ECONOMIC;
NEOPLASMS;
PATIENT SELECTION;
QUALITY OF LIFE;
TREATMENT OUTCOME;
|
|
EID: 84986550935
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2015.66.4201 Document Type: Letter |
|
Times cited : (10)
|
|
References (10)
|
